Results from Phase IIa clinical trial evaluating VT-111 reported by Viron Therapeutics

19. November 2009 00:49

Viron Therapeutics Inc., a biotechnology company pioneering the development of immune-modulating protein therapeutics derived from pathogens, today reported results from a Phase IIa clinical trial evaluating VT-111 (Serp-1), an anti-inflammatory protein derived from the myxoma virus. [More]

259b6317-e2c9-41a9-839b-c824711a233a|0|.0

Posted in: Drug Trial News | Pharmaceutical News

Tags: Anti-Inflammatory, Arthritis, Biomarker, Biotechnology, Cardiovascular Disease, Hospital, Macrophage, Rheumatoid Arthritis, Stent, Transplant, Ultrasound, Virus

Study to test anti-tumor effects of AEOL 10150 initiated

18. November 2009 03:04

Aeolus Pharmaceuticals, Inc. announced today the initiation of a study to test the anti-tumor effects of AEOL 10150 when combined with radiation and chemotherapy in nude mice bearing human non-small cell lung cancer (NSCLC) xenografts. [More]

9cc6e5d3-b581-4e45-8159-6d64d2a5c2da|0|.0

Posted in: Medical Science News | Medical Condition News | Pharmaceutical News

Tags: Angiogenesis, Anti-Inflammatory, Antioxidant, Cancer, Cell, Chemotherapy, Epilepsy, Fibrosis, Hypoxia, Lung Cancer, Macrophage, Manganese, Non-Small Cell Lung Cancer, Oxidative Stress, Paclitaxel, Radiation Exposure, Radiation Therapy, Radiotherapy, Small Cell Lung Cancer, Stress, Toxicology, VEGF, Weight Loss

Assessing the neurology market and its major players

17. November 2009 04:13

Research and Markets (http://www.researchandmarkets.com/research/63cb3f/dealmaking_and_ind) has announced the addition of Decision Resources, Inc.'s new report "Dealmaking and Industry Outlook: Neurological Disease" to their offering. [More]

3cce24a5-df8d-4ff4-91db-360afa454a74|0|.0

Posted in: Medical Condition News

Tags: Alzheimer's Disease, Autophagy, Calcium, Cell, Epilepsy, Fibroblast, Gene Therapy, Huntington's Disease, Immunotherapy, Insomnia, Macrophage, Migraine, Multiple Sclerosis, Myelin, Neurological Disease, Neurology, Parkinson's Disease, Pfizer, Potassium, Potassium Channel, Restless Legs Syndrome, Stem Cell, Stroke

Indefinite expansion of adult cells without recourse to stem cell intermediates possible

16. November 2009 07:34

Is the indefinite expansion of adult cells possible without recourse to stem cell intermediates? The team led by Michael Sieweke at the Centre d'immunologie de Marseille Luminy (Université Aix-Marseille 2 / CNRS / INSERM) has proved that this is the case by achieving the ex vivo regeneration for several months of macrophages, specialized cells in the immune system. [More]

bb568c64-b805-45fe-99d3-3119447e0e11|1|5.0

Posted in: Medical Science News

Tags: Brain, Cell, Macrophage, Stem Cell

Nuvo Research announces new licensing agreement for Oxoferin

12. November 2009 03:07

Nuvo Research Inc., a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced a new licensing agreement for Oxoferin(TM), its topical wound healing agent, and additional details of the funding assistance to be provided by the Development Bank of Saxony for the development of WF10. [More]

922ef69d-cb26-41b9-aac6-199d5dca9bc3|0|.0

Posted in: Business / Finance | Pharmaceutical News

Tags: Anti-Inflammatory, Arthritis, Atherosclerosis, Cancer, Cell, Diabetes, Drug Delivery, Immunology, Macrophage, Rheumatoid Arthritis, Rhinitis, Wound Healing

Data from Phase IIa clinical trial evaluating VT-111 to be presented by Viron Therapeutics at AHA conference

12. November 2009 01:33

Viron Therapeutics Inc., a biopharmaceutical company pioneering the development of viral protein therapeutics, announced today that the Company's research collaborator, Dr. Jean-Claude Tardif, Director of the Research Center at the Montreal Heart Institute, will present data from a Phase IIa clinical trial evaluating VT-111 at the American Heart Association (AHA) Scientific Sessions 2009 conference. The conference will take place in Orlando, Florida from November 14 to 18, 2009. [More]

c71b5b14-70bd-4774-a777-06f779c2da78|0|.0

Posted in: Drug Trial News

Tags: Anti-Inflammatory, Arthritis, Cardiovascular Disease, Macrophage, Rheumatoid Arthritis, Transplant

Peregrine Pharmaceuticals' bavituximab PS-targeting antibody demonstrates potent anti-tumor activity

11. November 2009 01:51

Peregrine Pharmaceuticals, Inc. today announced that a newly published study shows that a phosphatidylserine (PS)-targeting antibody similar to the company's lead product candidate bavituximab demonstrated potent anti-tumor activity when combined with radiation in a model of aggressive brain cancer, doubling the survival time of test animals and producing long-term cures. [More]

1b5117db-1e00-402b-9f30-3052db1f8ace|2|5.0

Posted in: Medical Science News | Medical Condition News

Tags: Antibody, Brain, Brain Cancer, Brain Tumor, Breast Cancer, Cancer, Chemotherapy, Glioblastoma, Lung Cancer, Macrophage, Pharmacology, Radiation Therapy, Radiotherapy

Study demonstrates potential of human Serum Amyloid P to block very aggressive fibrotic pathology

5. November 2009 01:33

Promedior, Inc., a leader in the development of novel therapeutics for the treatment of fibrotic diseases and tissue remodeling, announced today the publication of results from preclinical studies demonstrating that human Serum Amyloid P (hSAP) potently inhibited fibrosis in two independent model systems of kidney fibrosis. [More]

de7a234c-409c-4530-96d2-05bbdc985cb9|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Anti-Inflammatory, Cell, Collagen, Fibrosis, Gene Expression, Hospital, Macrophage, Pathology, Transplant

Promedior granted European Orphan Medicinal Product Designation for PRM-151

29. October 2009 08:22

Promedior, Inc., a leader in the development of novel therapeutics for the treatment of fibrotic diseases and tissue remodeling, announced today that the European Commission has granted Orphan Medicinal Product Designation to its lead drug candidate PRM-151 for use in the prevention of scarring post glaucoma filtration surgery. [More]

32a5fb17-f11a-43ee-907b-226810f6da73|0|.0

Posted in: Drug Trial News | Disease/Infection News

Tags: Blindness, Cell, Fibrosis, Fistula, Glaucoma, Macrophage, Neuropathy

Pregnant women with symptoms of depression have a stronger biological reaction to the seasonal flu vaccine

29. October 2009 01:05

Pregnant women with significant symptoms of depression tend to have a stronger biological reaction to the seasonal flu vaccine than do women with lower depression levels, according to a new study. [More]

f5b21024-666f-4d62-87d7-8a31567fce7d|1|5.0

Posted in: Women's Health News | Disease/Infection News

Tags: Blood Pressure, Brain, CDC, Cytokines, Depression, Genetics, H1N1, Immunology, Influenza, Interleukin-6, Macrophage, Pregnancy, Psychiatry, Psychology, Smoking, Stress, Vaccine

Doctoral candidate sheds new light on the biology of Leishmania parasites

24. October 2009 05:39

Professor Albert Descoteaux's team at Centre INRS - Institut Armand-Frappier has gained a better understanding of how the Leishmania donovani parasite manages to outsmart the human immune system and proliferate with impunity, causing visceral leishmaniasis, a chronic infection that is potentially fatal if left untreated. [More]

67472b0b-f2e9-4956-9675-3e188fe8f3c2|0|.0

Posted in: Medical Condition News | Disease/Infection News

Tags: Bone, Bone Marrow, Leishmaniasis, Macrophage

Positive data from BioSante Pharmaceuticals' LibiGel Phase III clinical development program

20. October 2009 08:06

BioSante Pharmaceuticals, Inc., today announced positive safety data in its ongoing LibiGel Phase III clinical development program. For the first time, unblinded data have been reviewed by the independent DMC of the LibiGel Cardiovascular and Breast Cancer Safety Study. Based on this review of unblinded data, the DMC unanimously recommended continuation of the study as described in the study protocol, with no modifications. [More]

2c555215-3ddc-4cc8-a58d-a1c70fd81e76|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Breast Cancer, Calcium, Cancer, Cell, Contraception, Diabetes, Drug Delivery, Estradiol, Estrogen, H1N1, Macrophage, Menopause, New Drug Application, Sexual Dysfunction, Stroke, Swine Flu, Testosterone, Vaccine

Biosante Pharmaceuticals, Cell Genesys successfully complete merger

15. October 2009 00:43

BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc., today announced the successful completion of their previously announced merger of Cell Genesys with and into BioSante, with BioSante as the surviving company, under which BioSante now has acquired all of the outstanding shares of Cell Genesys common stock. [More]

74bc71ad-81f1-40ea-a926-6bc52108bb98|0|.0

Posted in: Business / Finance

Tags: Bone, Breast Cancer, Calcium, Cancer, Cell, Contraception, Drug Delivery, Estradiol, Estrogen, H1N1, Hospital, Leukemia, Macrophage, Menopause, New Drug Application, Pancreatic Cancer, Prostate Cancer, Sexual Dysfunction, Swine Flu, Testosterone, Vaccine

RXi Pharmaceuticals presents new preclinical data from its advanced RNAi therapeutic platform

9. October 2009 06:49

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced the presentation of new preclinical data from its advanced RNAi therapeutic platform at its Annual Investor Event held in New York City on Monday, October 5, 2009. [More]

ed7dbb78-2b55-4f31-b2b0-af1372a5383a|0|.0

Posted in: Medical Science News

Tags: Cell, Hypercholesterolemia, Macrophage, Oncology, RNAi Therapeutics, siRNA

Plexxikon commences patient dosing in PLX3397 Phase 1 clinical trial

9. October 2009 05:32

Plexxikon Inc. today announced that dosing of cancer patients with PLX3397 has started in a Phase 1 clinical trial. PLX3397 is a novel, oral investigational drug for treating multiple diseases, including metastatic cancer and rheumatoid arthritis. [More]

01a2ea18-6ef0-414e-ba82-f78beafc4149|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Arthritis, Autoimmune Disease, Biotechnology, Bone, Brain, Brain Cancer, Cancer, Cell, Cell Proliferation, Colorectal Cancer, Cytokines, Diabetes, Kidney Disease, Kinase Inhibitor, Lupus, Macrophage, Melanoma, Multiple Sclerosis, Neurofibromatosis, Oncology, Rheumatoid Arthritis

Free!

Recent Comments

Twitter

Information

Macrophage News and Research

Results from Phase IIa clinical trial evaluating VT-111 reported by Viron Therapeutics

Study to test anti-tumor effects of AEOL 10150 initiated

Assessing the neurology market and its major players

Indefinite expansion of adult cells without recourse to stem cell intermediates possible

Nuvo Research announces new licensing agreement for Oxoferin

Data from Phase IIa clinical trial evaluating VT-111 to be presented by Viron Therapeutics at AHA conference

Peregrine Pharmaceuticals' bavituximab PS-targeting antibody demonstrates potent anti-tumor activity

Study demonstrates potential of human Serum Amyloid P to block very aggressive fibrotic pathology

Promedior granted European Orphan Medicinal Product Designation for PRM-151

Pregnant women with symptoms of depression have a stronger biological reaction to the seasonal flu vaccine

Doctoral candidate sheds new light on the biology of Leishmania parasites

Positive data from BioSante Pharmaceuticals' LibiGel Phase III clinical development program

Biosante Pharmaceuticals, Cell Genesys successfully complete merger

RXi Pharmaceuticals presents new preclinical data from its advanced RNAi therapeutic platform

Plexxikon commences patient dosing in PLX3397 Phase 1 clinical trial

Recent Articles

Free!

Recent Comments

Twitter

Information

Macrophage News and Research

Medical News Cloud

Recent Articles